Cytokinetics analyst coverage
WebMar 31, 2024 · Mar. 31, 2024, 04:01 PM Over the past 3 months, 13 analysts have published their opinion on Cytokinetics (NASDAQ:CYTK) stock. These analysts are typically employed by large Wall Street banks and... WebSep 28, 2024 · News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders
Cytokinetics analyst coverage
Did you know?
WebApr 5, 2024 · Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. INVESTORS & … WebCYTK Stock 12 Months Forecast. $58.50. (66.24% Upside) Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19.
WebApr 12, 2024 · Wall Street Analyst Weigh In. Several brokerages recently weighed in on CYTK. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a ...
WebMar 31, 2024 · Analyst Coverage; Investor FAQ; IR Contacts; Corporate Governance; Information Request; Email Alerts WebCytokinetics was founded by pioneers in the field of muscle biology. This team of forward-thinking scientists set out a vision for translating their expertise into new insights and approaches to novel drug discovery.
WebApr 6, 2024 · Analyst Price Forecast Suggests 12.99% Upside As of April 6, 2024, the average one-year price target for Broadcom is $696.81. The forecasts range from a low of $589.84 to a high of $787.50.
WebMar 3, 2024 · Following the latest upgrade, the current consensus, from the 13 analysts covering Cytokinetics, is for revenues of US$54m in 2024, which would reflect a stressful 43% reduction in... shsu hr officeWebApr 10, 2024 · Trevor Immelman faced the tall task of being named CBS Sports’ lead golf analyst in January, replacing Nick Faldo in the 18th tower, but he soared into this weekend’s coverage of the Masters. theory virtue crosswordWebMar 7, 2024 · Cytokinetics (CYTK) Analysts Prediction, Stock Forecast & Price Targets - Simply Wall St View Valuation Cytokinetics Future Growth Future criteria checks 0/6 Cytokinetics, Incorporated's earnings is forecasted to decline at 23.5% and its revenue is expected to decline at 46.6%. shsu it supportWebApr 2, 2024 · Financials. In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods of 2024. This ... shsu junior hoursWebJan 9, 2024 · By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 14% per year. ... We have analyst estimates for Cytokinetics ... shsu job searchWebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ... theory virtue danwordWebCytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. Stock Information Press Releases shsu linkedin learning